Month: April 2022

Regulated Information Nyrstar NV 2021 Full Year Results 13 April 2022 at 07:00 CEST Nyrstar NV (“Nyrstar” or the “Company”) is today announcing the publication of its financial statements for the twelve months ended 31 December 2021 (“Full Year Results 2021”). The Full Year Results 2021 have been prepared on a discontinuity basis as a result of the decision of the extraordinary shareholders’ meeting of 9 December 2019 to reject the continuation of the Company’s activities. The Company has received from its auditor, and is publishing today, an audit opinion to accompany its Full Year Results 2021. In its audit opinion, the auditor confirms that in its opinion, the annual accounts give a true and fair view of the Company’s net equity and financial position as of 31 December 2021, as well as of its results for the year then...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, April 13, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Shabir Hasham, MD, as Chief Medical Officer (CMO) and a member of Santhera’s Executive Management team, effective May 1, 2022. Shabir has served as Santhera’s Global Development Program Lead & Global Head Medical Affairs for the past three years. In this role, Shabir was primarily responsible for overseeing the clinical development and regulatory submission of vamorolone for the treatment of Duchenne muscular dystrophy (DMD), which culminated in the start of the rolling NDA submission to the U.S. FDA in March 2022, and for supporting launch preparations for this lead product candidate. He previously served as Santhera’s Head of Medical Affairs EU & RoW. Before joining Santhera in...

MCH Group plans a further capital increase with the support of its two main shareholdersMCH Group is planning a further capital increase in order to secure liquidity for the refinancing of its CHF 100 million bond and the further development of the company. The government of the Canton of Basel-Stadt is asking the cantonal parliament to participate in the planned capital increase with an amount of up to CHF 34 million. Under this condition, Lupa Systems will also invest up to CHF 34 million in the company. The capital increase is to be carried out with subscription rights for all shareholders. Following the pandemic-related losses of the past two years, a financial package of measures is required in order to secure the refinancing of the CHF 100 million bond due in May 2023 and the necessary investments in the company’s growth....

Top-line Data Scheduled to Report in Q2 2022 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 13, 2022 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that patient enrollment has been completed in its Phase 2a clinical study evaluating dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles. Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm. A total of 15 patients have been enrolled into this double-blind, placebo controlled Phase 2a feasibility study. The...

Press ReleaseRegulated Information13 April 2022, 7:00 am CET, Antwerp, Belgium   The shareholders of VGP NV (the “Company”) are hereby invited to attend the annual shareholders’ meeting and the extraordinary and special shareholders’ meeting (the “Meetings”) which shall consecutively take place at Botanic Sanctuary Antwerp (room Amaryllis), Leopoldstraat 26, 2000 Antwerp, Belgium, on Friday 13 May 2022 at 10:00 am. Please consult the website link: www.vgpparks.eu/en/investors/shareholder-meetings/ for further information concerning the agenda, admission conditions and voting modalities for the Meetings. The board of directors CONTACT DETAILS FOR INVESTORS AND MEDIA ENQUIRIESInvestor Relations Tel: +32 (0)3 289 1433investor.relations@vgpparks.euPetra Vanclova (External Communications) Tel: +42 602 262 107  ABOUT VGP VGP is a...

Amsterdam, April 13, 2022: Arcadis (EURONEXT: ARCAD) – Water pipes in parts of South Yorkshire in the UK could be used to speed up the roll-out of faster broadband without digging up roads, under UK Government plans to trial innovative new technology to boost digital connectivity across the country. This ground-breaking project, delivered by Yorkshire Water working with Arcadis and University of Strathclyde, will test solutions involving putting fibre sensors inside the water pipes. The first trial of its kind in the UK, it will also explore how fibre can help the water industry detect and repair leaks, often before they cause a problem for consumers. This will help water companies operate more efficiently and lower the carbon cost of drinking water. Under the proposals, fibre-optic cables would be deployed through 17 kilometres...

Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, reported today that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA. BAL0891 is a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division leading to tumor cell death. A first poster showed in-vitro data on the activity of BAL0891 against its targets, threonine tyrosine kinase (TTK) and polo-like-kinase 1 (PLK1). The activity of BAL0891 led to a faster disruption...

Mowi ASA (OSE:MOWI): Q1 2022 Trading update Harvest volumes Q1 2022 (1)Farming Norway 59.5 thousand tonnesFarming Scotland 10.5 thousand tonnesFarming Chile 16.0 thousand tonnesFarming Canada 9.0 thousand tonnesFarming Ireland 1.0 thousand tonnesFarming Faroes 1.0 thousand tonnesTotal 97.0 thousand tonnes   In connection with the presentation of the Q4 2021 results, Mowi ASA guided a total harvest volume of 98 thousand tonnes (GWE) for Q1 2022. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWE). Additional information Operational EBIT for the Group was approximately EUR 207 million in Q1 2022 (EUR 109 million in Q1 2021). Blended Farming cost per kg harvested was EUR 4.77. Total Operational EBIT per kg through the value chain was approximately as follows:Norway EUR 2.55Scotland EUR 1.00Chile EUR 1.25Canada EUR 2.55  Ireland EUR 3.70Faroes EUR 1.50     Operational...